Literature DB >> 29498309

Temperature-sensitive liposomal ciprofloxacin for the treatment of biofilm on infected metal implants using alternating magnetic fields.

Imalka Munaweera1, Sumbul Shaikh1, Danny Maples2, Adane S Nigatu2, Sri Nandhini Sethuraman2, Ashish Ranjan2, David E Greenberg3,4, Rajiv Chopra1,5.   

Abstract

Implants are commonly used as a replacement for damaged tissue. Many implants, such as pacemakers, chronic electrode implants, bone screws, and prosthetic joints, are made of or contain metal. Infections are one of the difficult to treat complications associated with metal implants due to the formation of biofilm, a thick aggregate of extracellular polymeric substances (EPS) produced by the bacteria. In this study, we treated a metal prosthesis infection model using a combination of ciprofloxacin-loaded temperature-sensitive liposomes (TSL) and alternating magnetic fields (AMF). AMF heating is used to disrupt the biofilm and release the ciprofloxacin-loaded TSL. The three main objectives of this study were to (1) investigate low- and high-temperature-sensitive liposomes (LTSLs and HTSLs) containing the antimicrobial agent ciprofloxacin for temperature-mediated antibiotic release, (2) characterise in vitro ciprofloxacin release and stability and (3) study the efficacy of combining liposomal ciprofloxacin with AMF against Pseudomonas aeruginosa biofilms grown on metal washers. The release of ciprofloxacin from LTSL and HTSL was assessed in physiological buffers. Results demonstrated a lower transition temperature for both LTSL and HTSL formulations when incubated in serum as compared with PBS, with a more pronounced impact on the HTSLs. Upon combining AMF with temperature-sensitive liposomal ciprofloxacin, a 3 log reduction in CFU of Pseudomonas aeruginosa in biofilm was observed. Our initial studies suggest that AMF exposure on metal implants can trigger release of antibiotic from temperature sensitive liposomes for a potent bactericidal effect on biofilm.

Entities:  

Keywords:  Biofilm; alternating magnetic fields; ciprofloxacin; metal implants; temperature sensitive liposomes

Mesh:

Substances:

Year:  2018        PMID: 29498309      PMCID: PMC6034688          DOI: 10.1080/02656736.2017.1422028

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  44 in total

Review 1.  Prosthetic joint infection.

Authors:  Paloma Anguita-Alonso; Arlen D Hanssen; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2005-10       Impact factor: 5.091

2.  Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE-PEG2000) on the thermal transition and release of doxorubicin.

Authors:  David Needham; Ji-Young Park; Alexander M Wright; Jihong Tong
Journal:  Faraday Discuss       Date:  2013       Impact factor: 4.008

3.  Targeted antibiotic delivery using low temperature-sensitive liposomes and magnetic resonance-guided high-intensity focused ultrasound hyperthermia.

Authors:  Rachel Wardlow; Chenchen Bing; Joshua VanOsdol; Danny Maples; Michelle Ladouceur-Wodzak; Michele Harbeson; Joris Nofiele; Robert Staruch; Akhilesh Ramachandran; Jerry Malayer; Rajiv Chopra; Ashish Ranjan
Journal:  Int J Hyperthermia       Date:  2016-02-18       Impact factor: 3.914

4.  Localised drug release using MRI-controlled focused ultrasound hyperthermia.

Authors:  Robert Staruch; Rajiv Chopra; Kullervo Hynynen
Journal:  Int J Hyperthermia       Date:  2010-12-15       Impact factor: 3.914

5.  Development of an in vitro drug release assay of PEGylated liposome using bovine serum albumin and high temperature.

Authors:  Atsuko Hioki; Ai Wakasugi; Kumi Kawano; Yoshiyuki Hattori; Yoshie Maitani
Journal:  Biol Pharm Bull       Date:  2010       Impact factor: 2.233

6.  Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia.

Authors:  Martin H Ellbogen; Keith M Olsen; Martha J Gentry-Nielsen; Laurel C Preheim
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

7.  Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia.

Authors:  Hui Xin Ong; Daniela Traini; David Cipolla; Igor Gonda; Mary Bebawy; Helen Agus; Paul M Young
Journal:  Pharm Res       Date:  2012-07-26       Impact factor: 4.200

8.  In depth study on thermosensitive liposomes: Optimizing formulations for tumor specific therapy and in vitro to in vivo relations.

Authors:  Wouter J M Lokerse; Esther C M Kneepkens; Timo L M ten Hagen; Alexander M M Eggermont; Holger Grüll; Gerben A Koning
Journal:  Biomaterials       Date:  2015-12-22       Impact factor: 12.479

Review 9.  Prosthetic joint infection.

Authors:  Aaron J Tande; Robin Patel
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

10.  Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

Authors:  David J Serisier; Diana Bilton; Anthony De Soyza; Philip J Thompson; John Kolbe; Hugh W Greville; David Cipolla; Paul Bruinenberg; Igor Gonda
Journal:  Thorax       Date:  2013-05-16       Impact factor: 9.139

View more
  3 in total

Review 1.  Biological and Physiochemical Methods of Biofilm Adhesion Resistance Control of Medical-Context Surface.

Authors:  Yuanzhe Li; Xiang Li; Yu Hao; Yang Liu; ZhiLi Dong; Kexin Li
Journal:  Int J Biol Sci       Date:  2021-04-23       Impact factor: 6.580

2.  Induction heating for eradicating Staphylococcus epidermidis from biofilm.

Authors:  Bart G Pijls; Ingrid M J G Sanders; Ed J Kujiper; Rob G H H Nelissen
Journal:  Bone Joint Res       Date:  2020-05-16       Impact factor: 5.853

3.  Alternating magnetic fields and antibiotics eradicate biofilm on metal in a synergistic fashion.

Authors:  Qi Wang; Jonathan Vachon; Bibin Prasad; Christine A Pybus; Norman Lapin; Rajiv Chopra; David E Greenberg
Journal:  NPJ Biofilms Microbiomes       Date:  2021-08-12       Impact factor: 8.462

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.